Cargando…
The Second Life of Methylarginines as Cardiovascular Targets
Endogenous methylarginines were proposed as cardiovascular risk factors more than two decades ago, however, so far, this knowledge has not led to the development of novel therapeutic approaches. The initial studies were primarily focused on the endogenous inhibitors of nitric oxide synthases asymmet...
Autores principales: | Jarzebska, Natalia, Mangoni, Arduino A., Martens-Lobenhoffer, Jens, Bode-Böger, Stefanie M., Rodionov, Roman N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769906/ https://www.ncbi.nlm.nih.gov/pubmed/31533264 http://dx.doi.org/10.3390/ijms20184592 |
Ejemplares similares
-
Homoarginine and methylarginines independently predict long-term outcome in patients presenting with suspicion of venous thromboembolism
por: Rodionov, Roman N., et al.
Publicado: (2021) -
Diabetes-linked transcription factor HNF4α regulates metabolism of endogenous methylarginines and β-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2
por: Burdin, Dmitry V., et al.
Publicado: (2016) -
A Novel Pathway for Metabolism of the Cardiovascular Risk Factor Homoarginine by alanine:glyoxylate aminotransferase 2
por: Rodionov, Roman N., et al.
Publicado: (2016) -
Knock-out of the critical nitric oxide synthase regulator DDAH1 in mice impacts amphetamine sensitivity and dopamine metabolism
por: Kozlova, Alena A., et al.
Publicado: (2023) -
Serum Methylarginines and Spirometry-Measured Lung Function in Older Adults
por: McEvoy, Mark A., et al.
Publicado: (2013)